TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06231004

Intervention type: PROCEDURE
Intervention: glucocorticosteroid and surgery
Description: Take glucocorticosteroid at once in the morning and use the following course of treatment: 6 tablets/day for 7 days-- 5 tablets/day for 2 days-- 4 tablets/day for 2 days-- 3 tablets/day for 2 days-- 2 tablets/day for 2 days-- 1 tablets/day for 2 days--surgery
Study: NCT00664690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celebrex
Description: 400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
Study: NCT06057935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Possible substitution with carboplatin based on clinician discretion
Study: NCT04690998

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Samples
Description: Genetic, proteomic, neurofilament analysis

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Samples
Description: Genetic, proteomic, neurofilament analysis

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Spinal and muscular MRI

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Spinal and muscular MRI
Study: NCT05363644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioDFence G3
Description: Placement of a sheet of BioDFence® G3 will be applied to the neurovascular bundle on participants undergoing an elective Full Nerve Sparing Radical Prostatectomy for primary treatment of prostate cancer.
Study: NCT06117657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose KL-HIV-Tri01
Description: Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^11 vg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle dose KL-HIV-Tri01
Description: Subjects will be dosed with single dose of KL-HIV-Tri01 at 8.0x10\^11 vg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose KL-HIV-Tri01
Description: Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^12 vg/kg.
Study: NCT00664690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo given preop and BID postop
Study: NCT06289998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamibarotene
Description: Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are administrated to placebo in daily for 52 weeks.
Study: NCT06341842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapaglifloziin 10 mg 1 tab daily
Study: NCT04673864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386
Description: QD, PO
Study: NCT06379880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTINUUM+ CONNECT remote monitoring
Description: CONTINUUM+ CONNECT is a web platform, accessible via the internet, which contains the digital medical device (DMN) Continuum+ alert module. This is a medical software intended for the interpretation of clinical constants, symptoms, adverse events and pain, generating alerts with a view to improving the monitoring of patients undergoing anticancer treatment. The Continuum+ Alert Module version 1.0.0 dated 30 April 2021 is CE-marked and will be used in accordance with the manufacturer's instructions for use by patients in the experimental group.
Study: NCT04718610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic intervention
Description: Nerve vagus stimulation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CRP assessment
Description: Blood CRP will be assessed during trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRP assessment
Description: Blood CRP will be assessed during trial

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QLQ-C30 questionnaire
Description: Completion of QLQ-C30

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QLQ-C30 questionnaire
Description: Completion of QLQ-C30
Study: NCT05295342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Means No intervention Girls' Curriculum
Description: The No Means No (NMN) Girls' Curriculum is a violence prevention program designed for adolescent girls and young women 10-20 years old. This curriculum has been designed specifically for safer implementation during the COVID-19 pandemic. NMN Girls' programming is deeply rooted in Empowerment Self-Defense, which is a uniquely holistic, survivor-centered, feminist approach to self-protection skills. Youth educators called Instructors deliver the curriculum to young people in schools. This 8-hour intervention is comprised of classes that teach young people mental, verbal and physical self-defense skills that can be used to prevent sexual assault and other forms of gender-based violence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Means No intervention Boys' Curriculum
Description: The No Means No (NMN) Boys' Curriculum is a violence prevention curriculum that has been designed specifically for implementation during the COVID-19 pandemic. Designed for adolescent boys and young men age 10-20. Like the girls program it is delivered by youth educators called Instructors in schools. This 8-hour intervention is comprised of classes that teach young people gender equitable attitudes, skills to defend equality and how to avoid violence as a power paradigm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Life Orientation
Description: The standard school-based Life Orientation curriculum
Study: NCT04673864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D012, D326, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D012, D326, D337
Description: QD, PO
Study: NCT05793307

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC301
Description: GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC301
Description: GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
Study: NCT05288712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training protocol
Description: Conventional training protocol
Study: NCT04475835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
Study: NCT05793307

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC301
Description: GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
Study: NCT06154694

Intervention type: RADIATION
Intervention: Stereo Radiographic EOS Measurements
Description: Healthy control will undergo a stereo radiographic EOS exam with their arm in various positions.~1. Relaxed standing (0 degree of abduction)~2. 45 degree of abduction in the coronal plane~3. 90 degree of abduction in the coronal plane~4. 120 degree of abduction in the coronal plane~5. 45 degree anterior flexion in the sagittal plane~6. 90 degree anterior flexion in the sagittal plane~7. 120 degree of anterior flexion in the sagittal plane~8. 45 degree extension in the sagittal plane
Study: NCT06400277

Intervention type: OTHER
Group type: OTHER
Intervention: Edentulous maxilla final impression for complete denture
Description: Final impressions of edentulous maxilla separated in two groups. In physical impression group stock and individual trays and physical impression materials used.

Intervention type: OTHER
Group type: OTHER
Intervention: Edentulous maxilla final impression for complete denture
Description: Final impressions of edentulous maxilla separated in two groups. In physical impression group stock and individual trays and physical impression materials used.

Intervention type: OTHER
Group type: OTHER
Intervention: Edentulous maxilla final impression for complete denture
Description: Final impressions of edentulous maxilla separated in two groups. In physical impression group stock and individual trays and physical impression materials used.

Intervention type: OTHER
Group type: OTHER
Intervention: Edentulous maxilla final impression for complete denture
Description: Final impressions of edentulous maxilla separated in two groups. In physical impression group stock and individual trays and physical impression materials used.

Intervention type: OTHER
Group type: OTHER
Intervention: Edentulous maxilla final impression for complete denture
Description: Final impressions of edentulous maxilla separated in two groups. In physical impression group stock and individual trays and physical impression materials used.
Study: NCT05567263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bulk-fill resin composite, (3M, ESPE)
Description: Teeth will be restored with Bulk-fill resin composite, (3M, ESPE)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surefil one™ Self-Adhesive Composite Hybrid
Description: teeth will be restored with Surefil one™ Self-Adhesive Composite Hybrid
Study: NCT06476951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Physical Activity Program
Description: The program includes online education, parent-child games, parent-child dancing, and other parent-child physical activity activities.
Study: NCT06255158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INSIGHT Program
Description: INSIGHT Program:~the program targets the reduction of EMSs' interference in social information processing, which may otherwise lead to the use of deviant behavior to fulfill emotional and sexual needs. Furthermore, the program has specific goals: (1) developing insight about the offense cycle; (2) fostering empathy for victims; (3) enhancing intimate and social/ interpersonal skills; (4) increasing emotional regulation skills.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual (TAU)
Description: TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
Study: NCT05477095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-313
Description: A synthetic peptide-based immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-313
Description: A synthetic peptide-based immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-313
Description: A synthetic peptide-based immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-313
Description: A synthetic peptide-based immunotherapy

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT06417294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D health education model
Description: explanation combined with 3D printed health education model

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional education
Description: Regular education
Study: NCT06408077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water administration
Description: Intravenous administration of water (Aqua ad injectabilia) until a decrease of plasma sodium of 5 to 8 mmol/l has been achieved
Study: NCT06214338

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 2.5, separated by 1 hour and 15 min.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose
Description: Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 5 separated by 1 hour and 15 min.
Study: NCT06418100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The recto intercostal fascial plane block
Description: After ensuring aseptic conditions, the high-frequency linear ultrasound probe was used to detect the rectus abdominis muscle and the 6-7th costal cartilage as described by Tulgar et al. After rotating and shifting the transducer, 6-7th costal cartilages, the rectus abdominis muscle, and intercostal muscles between the cartilages were confirmed. The primary investigator (B.C.) directed the needle tip caudad in the cephalic direction in-plainly, and 20 ml 0,25% bupivacaine was injected bilaterally into the plane between the costal cartilage and the rectus abdominis muscle following negative aspiration.
Study: NCT05669495

Intervention type: DEVICE
Intervention: ANNE Vital Sign System
Description: The ANNE Vital Sign System is a wireless remote monitoring system consisting of two flexible, soft, and skin-mounted electronic devices for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings. The ANNE Vital Sign System integrates simultaneous synchronized ambulatory measurement of electrocardiography, photoplethysmography with derived pulse oximetry, pulse arrival time with derived beat-to-beat blood pressure, triaxial accelerometry, respiratory rate, and temperature, which would enable accurate measurement of sleep apnea. Indeed, in compelling in-laboratory preliminary data, we show the capacity for the ANNE Vital Sign System to detect and characterize sleep apnea in older patients. The ANNE Vital Sign System is non-invasive, flexible, easy to use, comfortable, and skin safe.
Study: NCT05070299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosexual Educational Partner Program (PEPP)
Description: A communication and intimacy promotion kit consisting of three modules devoted to information sharing, partner communication and activities for building intimacy.
Study: NCT05654662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corsodyl Original Dentifrice
Description: It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million \[ppm\] Fluoride ion \[F\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection Dentifrice
Description: It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
Study: NCT05766267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin (Rb) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Delamanid (D or DLM) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid is part of control regimen (HRZE).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Rifampin is part of control regimen (HRZE).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol is part of control regimen (HRZE).
Study: NCT05221996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance circuit training
Study: NCT05400408

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VOX
Description: Breath Biopsy Analysis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VOX
Description: Breath Biopsy Analysis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VOX
Description: Breath Biopsy Analysis
Study: NCT05221996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance circuit training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance circuit training
Study: NCT05653245

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RGD Peptide
Description: adhesion molecules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RGD Peptide
Description: adhesion molecules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RGD Peptide
Description: adhesion molecules
Study: NCT04737434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extremely low frequency electromagnetic field device
Description: with extremely low frequency electromagnetic wave deliver or not to participants during sleep.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: electromagnetic field with no wave
Description: electromagnetic field with no wave
Study: NCT04254692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Participants in the standard of care group will receive intraoperative injection of bupivacaine only to the abdominal wall
Study: NCT06477003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography
Description: The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography
Description: The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature Measurement
Description: The temperature of the skin will be measured prior to and after MSOT imaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature Measurement
Description: The temperature of the skin will be measured prior to and after MSOT imaging.
Study: NCT05999630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial Tears Methylcellulose
Description: Participants will self-administer the artificial tears according to the schedule.
Study: NCT05323604

Intervention type: OTHER
Intervention: Colectomy with anastomosis of any type
Description: Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
Study: NCT06245005

Intervention type: DEVICE
Intervention: Brain exercise gameplay on a portable electronic device
Description: Feasibility is defined as a 70% completion rate for at least 3 of the six brain exercise games in study participants from which a 'first gameplay score' can be determined. Investigators will also assess level of satisfaction with the brain exercise intervention and barriers to playing in the busy preoperative clinical settings as evaluated by a patient-centered questionnaire (Discharge Survey).

Intervention type: DEVICE
Intervention: Brain exercise gameplay on a portable electronic device
Description: Feasibility is defined as a 70% completion rate for at least 3 of the six brain exercise games in study participants from which a 'first gameplay score' can be determined. Investigators will also assess level of satisfaction with the brain exercise intervention and barriers to playing in the busy preoperative clinical settings as evaluated by a patient-centered questionnaire (Discharge Survey).
Study: NCT05362461

Intervention type: DIAGNOSTIC_TEST
Intervention: Near Infrared Transillumination
Description: Caries imaging detection technology.
Study: NCT06315972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clemastine (8 mg/day)
Description: add-on clemastine (8 mg/day) + aerobic exercise training
Study: NCT06331273

Intervention type: PROCEDURE
Intervention: Liver transplantation with No-touch technique
Description: The core principle of no-touch tumor surgery revolves around avoiding direct contact with the tumor or surrounding tissues as much as possible to minimize the release of cancer cells into the bloodstream or nearby tissues.

Intervention type: PROCEDURE
Intervention: Liver transplantation with No-touch technique
Description: The core principle of no-touch tumor surgery revolves around avoiding direct contact with the tumor or surrounding tissues as much as possible to minimize the release of cancer cells into the bloodstream or nearby tissues.
Study: NCT06315972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: add-on placebo + aerobic exercise training
Study: NCT05538949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB-203
Description: * Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~* Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1Drop, QD / Day1, BID / Day5\~Day8.